<DOC>
	<DOCNO>NCT00963105</DOCNO>
	<brief_summary>The purpose study determine safety effectiveness different dose regimen lenalidomide patient relapsed refractory chronic lymphocytic leukemia .</brief_summary>
	<brief_title>Study Lenalidomide Evaluate Safety Efficacy Patients With Relapsed Refractory Chronic Lymphocytic Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>Age ≥ 18 year time signing informed consent form Must able adhere study visit schedule protocol requirement Must document diagnosis Bcell CLL Must relapse refractory least 1 regimen treatment CLL . At least one prior treatment must include purine analogbased bendamustinebased regimen Must Eastern Cooperative Oncology Group ( ECOG ) performance status score ≤2 . Any serious medical condition , laboratory abnormality , psychiatric illness would prevent subject signing informed consent form Active infection require systemic antibiotic Systemic treatment Bcell CLL within 28 day initiation lenalidomide treatment Alemtuzumab therapy within 120 day initiate lenalidomide treatment Prior therapy lenalidomide History grade 4 rash due prior thalidomide treatment Planned autologous allogeneic bone marrow transplantation Central nervous system ( CNS ) involvement document spinal fluid cytology image . Uncontrolled hyperthyroidism hypothyroidism Venous thromboembolism within 12 month ≥ Grade2 neuropathy Uncontrolled autoimmune hemolytic anemia thrombocytopenia Disease transformation [ i.e . Richter 's Syndrome ( lymphoma ) prolymphocytic leukemia ] Participation clinical study take investigational therapy within 28 day prior initiate lenalidomide therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>